



Sen. Javier L. Cervantes

Filed: 5/6/2026

10400SB3421sam001

LRB104 16644 CCC 37273 a

1 AMENDMENT TO SENATE BILL 3421

2 AMENDMENT NO. _____. Amend Senate Bill 3421 by replacing
3 everything after the enacting clause with the following:

4 "Section 5. The Physician Assistant Practice Act of 1987
5 is amended by changing Sections 4, 6, 7, 7.5, 7.7, and 21 and
6 by adding Sections 7.8, 7.9, and 7.10 as follows:

7 (225 ILCS 95/4) (from Ch. 111, par. 4604)

8 (Section scheduled to be repealed on January 1, 2028)

9 Sec. 4. Definitions. In this Act:

10 1. "Department" means the Department of Financial and
11 Professional Regulation.

12 2. "Secretary" means the Secretary of Financial and
13 Professional Regulation.

14 3. "Physician assistant" means any person not holding an
15 active license or permit issued by the Department pursuant to
16 the Medical Practice Act of 1987 who has been certified as a

1 physician assistant by the National Commission on ~~the~~
2 Certification of Physician Assistants or an equivalent
3 successor agency. ~~and performs procedures in collaboration~~
4 ~~with a physician as defined in this Act. A physician assistant~~
5 ~~may perform such procedures within the specialty of the~~
6 ~~collaborating physician, except that such physician shall~~
7 ~~exercise such direction, collaboration, and control over such~~
8 ~~physician assistants as will assure that patients shall~~
9 ~~receive quality medical care. Physician assistants shall be~~
10 ~~capable of performing a variety of tasks within the specialty~~
11 ~~of medical care in collaboration with a physician.~~
12 ~~Collaboration with the physician assistant shall not be~~
13 ~~construed to necessarily require the personal presence of the~~
14 ~~collaborating physician at all times at the place where~~
15 ~~services are rendered, as long as there is communication~~
16 ~~available for consultation by radio, telephone or~~
17 ~~telecommunications within established guidelines as determined~~
18 ~~by the physician/physician assistant team. The collaborating~~
19 ~~physician may delegate tasks and duties to the physician~~
20 ~~assistant. Delegated tasks or duties shall be consistent with~~
21 ~~physician assistant education, training, and experience. The~~
22 ~~delegated tasks or duties shall be specific to the practice~~
23 ~~setting and shall be implemented and reviewed under a written~~
24 ~~collaborative agreement established by the physician or~~
25 ~~physician/physician assistant team. A physician assistant,~~
26 ~~acting as an agent of the physician, shall be permitted to~~

1 ~~transmit the collaborating physician's orders as determined by~~
2 ~~the institution's by laws, policies, procedures, or job~~
3 ~~description within which the physician/physician assistant~~
4 ~~team practices. Physician assistants shall practice only in~~
5 ~~accordance with a written collaborative agreement.~~

6 ~~Any person who holds an active license or permit issued~~
7 ~~pursuant to the Medical Practice Act of 1987 shall have that~~
8 ~~license automatically placed into inactive status upon~~
9 ~~issuance of a physician assistant license. Any person who~~
10 ~~holds an active license as a physician assistant who is issued~~
11 ~~a license or permit pursuant to the Medical Practice Act of~~
12 ~~1987 shall have his or her physician assistant license~~
13 ~~automatically placed into inactive status.~~

14 3.5. "Physician assistant practice" means the performance
15 of any medical service for which the physician assistant has
16 been prepared by the physician assistant's education,
17 training, and experience and is competent to perform as
18 determined through an employment agreement or the
19 credentialing and privileging system of a licensed facility.
20 Medical and surgical services provided by physician assistants
21 include, but are not limited to:

22 (A) obtaining and performing comprehensive health
23 histories and physical examinations;

24 (B) evaluating, diagnosing, managing, and providing
25 medical treatment;

26 (C) ordering, performing, and interpreting diagnostic

1 studies and therapeutic procedures;

2 (D) educating patients on health promotion and disease
3 prevention;

4 (E) providing consultation upon request;

5 (F) writing medical orders;

6 (G) prescribing, dispensing, ordering, administering,
7 and procuring drugs and medical devices; and

8 (H) assisting in surgery. ~~procedures within the~~
9 ~~specialty of the collaborating physician. Physician~~
10 ~~assistants shall be capable of performing a variety of~~
11 ~~tasks within the specialty of medical care of the~~
12 ~~collaborating physician. Collaboration with the physician~~
13 ~~assistant shall not be construed to necessarily require~~
14 ~~the personal presence of the collaborating physician at~~
15 ~~all times at the place where services are rendered, as~~
16 ~~long as there is communication available for consultation~~
17 ~~by radio, telephone, telecommunications, or electronic~~
18 ~~communications. The collaborating physician may delegate~~
19 ~~tasks and duties to the physician assistant. Delegated~~
20 ~~tasks or duties shall be consistent with physician~~
21 ~~assistant education, training, and experience. The~~
22 ~~delegated tasks or duties shall be specific to the~~
23 ~~practice setting and shall be implemented and reviewed~~
24 ~~under a written collaborative agreement established by the~~
25 ~~physician or physician/physician assistant team. A~~
26 ~~physician assistant shall be permitted to transmit the~~

1 ~~collaborating physician's orders as determined by the~~
2 ~~institution's bylaws, policies, or procedures or the job~~
3 ~~description within which the physician/physician assistant~~
4 ~~team practices. Physician assistants shall practice only~~
5 ~~in accordance with a written collaborative agreement,~~
6 ~~except as provided in Section 7.5 of this Act.~~

7 4. "Board" means the Illinois State Medical Board ~~Medical~~
8 ~~Licensing Board constituted under the Medical Practice Act of~~
9 ~~1987.~~

10 5. (Blank).

11 6. "Physician" means a person licensed to practice
12 medicine in all of its branches under the Medical Practice Act
13 of 1987.

14 7. "Collaborating physician" means the physician who,
15 within his or her specialty and expertise, may delegate a
16 variety of tasks and procedures to the physician assistant.
17 Such tasks and procedures shall be delegated in accordance
18 with a written collaborative agreement when the agreement is
19 required under this Act.

20 8. (Blank).

21 9. "Address of record" means the designated address
22 recorded by the Department in the applicant's application file
23 or the licensee's ~~application file or~~ license file, as
24 maintained by the Department's licensure maintenance unit.

25 10. "Hospital affiliate" means a corporation, partnership,
26 joint venture, limited liability company, or similar

1 organization, other than a hospital, that is devoted primarily
2 to the provision, management, or support of health care
3 services and that directly or indirectly controls, is
4 controlled by, or is under common control of the hospital. For
5 the purposes of this definition, "control" means having at
6 least an equal or a majority ownership or membership interest.
7 A hospital affiliate shall be 100% owned or controlled by any
8 combination of hospitals, their parent corporations, or
9 physicians licensed to practice medicine in all its branches
10 in Illinois. "Hospital affiliate" does not include a health
11 maintenance organization regulated under the Health
12 Maintenance Organization Act.

13 11. "Email address of record" means the designated email
14 address recorded by the Department in the applicant's
15 application file or the licensee's license file, as maintained
16 by the Department's licensure maintenance unit.

17 12. "Federally qualified health center" means a health
18 center funded under Section 330 of the federal Public Health
19 Service Act.

20 (Source: P.A. 102-1117, eff. 1-13-23; 103-65, eff. 1-1-24.)

21 (225 ILCS 95/6) (from Ch. 111, par. 4606)

22 (Section scheduled to be repealed on January 1, 2028)

23 Sec. 6. Physician assistant title.

24 (a) No physician assistant shall use the title of doctor,
25 physician, or associate with his or her name or any other term

1 that would indicate to other persons that the physician
2 assistant is a licensed physician ~~he or she is qualified to~~
3 ~~engage in the general practice of medicine.~~

4 (b) A physician assistant shall verbally identify himself
5 or herself as a physician assistant, including, when
6 applicable, specialty certification, to each patient.

7 (c) Nothing in this Act shall be construed to relieve a
8 physician assistant of the professional or legal
9 responsibility for the care and treatment of persons attended
10 by him or her.

11 (d) (Blank). ~~The collaborating physician shall file with~~
12 ~~the Department notice of employment, discharge, or~~
13 ~~collaboration with a physician assistant within 60 days of~~
14 ~~employment, discharge, or assumption of collaboration with a~~
15 ~~physician assistant. Nothing in this Section shall prevent a~~
16 ~~physician assistant from beginning his or her employment~~
17 ~~before the notice of employment or collaboration has been~~
18 ~~filed.~~

19 No person shall use the title physician assistant,
20 physician associate, PA, PA-C, or any other term that would
21 indicate to other persons that the person is a licensed or
22 board-certified physician assistant unless the person is
23 licensed as a physician assistant under this Act.

24 (Source: P.A. 102-735, eff. 1-1-23.)

1 (Section scheduled to be repealed on January 1, 2028)

2 Sec. 7. Collaboration requirements.

3 (a) A written collaborative agreement is required for all
4 physician assistants engaged in clinical practice prior to
5 satisfying the requirements of Section 7.9, except for
6 physician assistants who practice in a hospital, hospital
7 affiliate, federally qualified health center, or ambulatory
8 surgical treatment center as provided in Section 7.7.

9 (b) ~~(a)~~ A collaborating physician shall determine the
10 number of physician assistants to collaborate with, provided
11 the physician is able to provide adequate collaboration as
12 outlined in the written collaborative agreement required under
13 Section 7.5 of this Act and consideration is given to the
14 nature of the physician's practice, complexity of the patient
15 population, and the experience of each physician assistant. A
16 collaborating physician may collaborate with a maximum of 7
17 full-time equivalent physician assistants as described in
18 Section 54.5 of the Medical Practice Act of 1987. As used in
19 this Section, "full-time equivalent" means the equivalent of
20 40 hours per week per individual. Physicians and physician
21 assistants who work in a hospital, hospital affiliate,
22 federally qualified health center, or ambulatory surgical
23 treatment center as defined by Section 7.7 of this Act are
24 exempt from the collaborative ratio restriction requirements
25 of this Section. A physician assistant shall be able to hold
26 more than one professional position. A collaborating physician

1 shall file a notice of collaboration of each physician
2 assistant according to the rules of the Department.

3 (c) Physician assistants shall collaborate only with
4 physicians as defined in this Act who are engaged in clinical
5 practice, or in clinical practice in public health or other
6 community health facilities.

7 (d) Nothing in this Act shall be construed to limit the
8 delegation of tasks or duties by a physician to a nurse or
9 other appropriately trained personnel.

10 (e) Nothing in this Act shall be construed to prohibit the
11 employment of physician assistants by a hospital, nursing home
12 or other health care facility where such physician assistants
13 function with ~~under~~ a collaborating physician.

14 (f) A physician assistant may be employed by a practice
15 group or other entity employing multiple physicians at one or
16 more locations. In that case, one of the physicians practicing
17 at a location shall be designated the collaborating physician.
18 The other physicians with that practice group or other entity
19 who practice in the same general type of practice or specialty
20 as the collaborating physician may collaborate with the
21 physician assistant with respect to their patients.

22 (g) ~~(b)~~ A physician assistant licensed in this State, or
23 licensed or authorized to practice in any other U.S.
24 jurisdiction or credentialed by his or her federal employer as
25 a physician assistant, who is responding to a need for medical
26 care created by an emergency or by a state or local disaster

1 may render such care that the physician assistant is able to
2 provide without collaboration as it is defined in this Section
3 or with such collaboration as is available.

4 (h) Any physician who collaborates with a physician
5 assistant providing medical care in response to such an
6 emergency or state or local disaster shall not be required to
7 meet the requirements set forth in this Section for a
8 collaborating physician.

9 (Source: P.A. 103-65, eff. 1-1-24.)

10 (225 ILCS 95/7.5)

11 (Section scheduled to be repealed on January 1, 2028)

12 Sec. 7.5. Written collaborative agreements, ~~prescriptive~~
13 ~~authority.~~

14 (a) A written collaborative agreement is required for all
15 physician assistants to practice in the State, except as
16 provided in Sections ~~Section~~ 7.7 and 7.9 of this Act. When a
17 written collaborative agreement is required under this Act,
18 the following shall apply:

19 (1) A written collaborative agreement shall describe
20 the working relationship of the physician assistant with
21 the collaborating physician and shall describe the
22 categories of care, treatment, or procedures to be
23 provided by the physician assistant. ~~The written~~
24 ~~collaborative agreement shall promote the exercise of~~
25 ~~professional judgment by the physician assistant~~

1 ~~commensurate with his or her education and experience. The~~
2 ~~services to be provided by the physician assistant shall~~
3 ~~be services that the collaborating physician is authorized~~
4 ~~to and generally provides to his or her patients in the~~
5 ~~normal course of his or her clinical medical practice. The~~
6 ~~written collaborative agreement need not describe the~~
7 ~~exact steps that a physician assistant must take with~~
8 ~~respect to each specific condition, disease, or symptom~~
9 ~~but must specify which authorized procedures require the~~
10 ~~presence of the collaborating physician as the procedures~~
11 ~~are being performed.~~ The relationship under a written
12 collaborative agreement shall not be construed to require
13 the personal presence of a physician at the place where
14 services are rendered. Methods of communication shall be
15 available for consultation with the collaborating
16 physician in person or by telecommunications or electronic
17 communications as set forth in the written collaborative
18 agreement. ~~For the purposes of this Act, "generally~~
19 ~~provides to his or her patients in the normal course of his~~
20 ~~or her clinical medical practice" means services, not~~
21 ~~specific tasks or duties, the collaborating physician~~
22 ~~routinely provides individually or through delegation to~~
23 ~~other persons so that the physician has the experience and~~
24 ~~ability to collaborate and provide consultation.~~

25 (2) (Blank). ~~The written collaborative agreement shall~~
26 ~~be adequate if a physician does each of the following:~~

1 ~~(A) Participates in the joint formulation and~~
2 ~~joint approval of orders or guidelines with the~~
3 ~~physician assistant and he or she periodically reviews~~
4 ~~such orders and the services provided patients under~~
5 ~~such orders in accordance with accepted standards of~~
6 ~~medical practice and physician assistant practice.~~

7 ~~(B) Provides consultation at least once a month.~~

8 (3) A copy of the signed, written collaborative
9 agreement must be available to the Department upon request
10 ~~from both the physician assistant and the collaborating~~
11 ~~physician.~~

12 (4) A physician assistant shall inform each
13 collaborating physician of all written collaborative
14 agreements he or she has signed and provide a copy of these
15 to any collaborating physician upon request.

16 (b) To prescribe Schedule II, III, IV, or V controlled
17 substances under this Section, a physician assistant must
18 obtain a mid-level practitioner controlled substances license.
19 ~~A collaborating physician may, but is not required to,~~
20 ~~delegate prescriptive authority to a physician assistant as~~
21 ~~part of a written collaborative agreement. This authority may,~~
22 ~~but is not required to, include prescription of, selection of,~~
23 ~~orders for, administration of, storage of, acceptance of~~
24 ~~samples of, and dispensing medical devices, over the counter~~
25 ~~medications, legend drugs, medical gases, and controlled~~
26 ~~substances categorized as Schedule II through V controlled~~

1 ~~substances, as defined in Article II of the Illinois~~
2 ~~Controlled Substances Act, and other preparations, including,~~
3 ~~but not limited to, botanical and herbal remedies. The~~
4 ~~collaborating physician must have a valid, current Illinois~~
5 ~~controlled substance license and federal registration with the~~
6 ~~Drug Enforcement Administration to delegate the authority to~~
7 ~~prescribe controlled substances.~~

8 ~~(1) To prescribe Schedule II, III, IV, or V controlled~~
9 ~~substances under this Section, a physician assistant must~~
10 ~~obtain a mid-level practitioner controlled substances~~
11 ~~license. Medication orders issued by a physician assistant~~
12 ~~shall be reviewed periodically by the collaborating~~
13 ~~physician.~~

14 ~~(2) The collaborating physician shall file with the~~
15 ~~Department notice of delegation of prescriptive authority~~
16 ~~to a physician assistant and termination of delegation,~~
17 ~~specifying the authority delegated or terminated. Upon~~
18 ~~receipt of this notice delegating authority to prescribe~~
19 ~~controlled substances, the physician assistant shall be~~
20 ~~eligible to register for a mid-level practitioner~~
21 ~~controlled substances license under Section 303.05 of the~~
22 ~~Illinois Controlled Substances Act. Nothing in this Act~~
23 ~~shall be construed to limit the delegation of tasks or~~
24 ~~duties by the collaborating physician to a nurse or other~~
25 ~~appropriately trained persons in accordance with Section~~
26 ~~54.2 of the Medical Practice Act of 1987.~~

1 ~~(3) In addition to the requirements of this subsection~~
2 ~~(b), a collaborating physician may, but is not required~~
3 ~~to, delegate authority to a physician assistant to~~
4 ~~prescribe Schedule II controlled substances, if all of the~~
5 ~~following conditions apply:~~

6 ~~(A) Specific Schedule II controlled substances by~~
7 ~~oral dosage or topical or transdermal application may~~
8 ~~be delegated, provided that the delegated Schedule II~~
9 ~~controlled substances are routinely prescribed by the~~
10 ~~collaborating physician. This delegation must identify~~
11 ~~the specific Schedule II controlled substances by~~
12 ~~either brand name or generic name. Schedule II~~
13 ~~controlled substances to be delivered by injection or~~
14 ~~other route of administration may not be delegated.~~

15 ~~(B) (Blank).~~

16 ~~(C) Any prescription must be limited to no more~~
17 ~~than a 30 day supply, with any continuation authorized~~
18 ~~only after prior approval of the collaborating~~
19 ~~physician.~~

20 ~~(D) The physician assistant must discuss the~~
21 ~~condition of any patients for whom a controlled~~
22 ~~substance is prescribed monthly with the collaborating~~
23 ~~physician.~~

24 ~~(E) The physician assistant meets the education~~
25 ~~requirements of Section 303.05 of the Illinois~~
26 ~~Controlled Substances Act.~~

1 (c) Nothing in this Act shall be construed to limit the
2 delegation of tasks or duties by a physician to a licensed
3 practical nurse, a registered professional nurse, or other
4 persons. Nothing in this Act shall be construed to limit the
5 method of delegation that may be authorized by any means,
6 including, but not limited to, oral, written, electronic,
7 standing orders, protocols, guidelines, or verbal orders.
8 Nothing in this Act shall be construed to authorize a
9 physician assistant to provide health care services required
10 by law or rule to be performed by a physician. Nothing in this
11 Act shall be construed to authorize the delegation or
12 performance of operative surgery. Nothing in this Section
13 shall be construed to preclude a physician assistant from
14 assisting in surgery.

15 (c-5) Nothing in this Section shall be construed to apply
16 to any medication authority, including Schedule II controlled
17 substances of a licensed physician assistant for care provided
18 in a hospital, hospital affiliate, federally qualified health
19 center, or ambulatory surgical treatment center pursuant to
20 Section 7.7 of this Act, or to a physician assistant
21 satisfying the requirements of Section 7.9 of this Act.

22 (d) (Blank).

23 (e) Nothing in this Section shall be construed to prohibit
24 generic substitution.

25 (f) Delegation of prescriptive authority by a physician is
26 not required under this Section.

1 (Source: P.A. 102-558, eff. 8-20-21; 103-65, eff. 1-1-24;
2 103-605, eff. 7-1-24.)

3 (225 ILCS 95/7.7)

4 (Section scheduled to be repealed on January 1, 2028)

5 Sec. 7.7. Physician assistants in hospitals, hospital
6 affiliates, federally qualified health centers, or ambulatory
7 surgical treatment centers.

8 (a) A physician assistant may provide services in a
9 hospital as defined in the Hospital Licensing Act, a hospital
10 affiliate as defined in the University of Illinois Hospital
11 Act, a federally qualified health center, or a licensed
12 ambulatory surgical treatment center as defined in the
13 Ambulatory Surgical Treatment Center Act without a written
14 collaborative agreement pursuant to Section 7.5 of this Act
15 only in accordance with this Section. A physician assistant
16 must possess clinical privileges recommended by (i) the
17 hospital medical staff and granted by the hospital, (ii) the
18 physician committee and federally qualified health center, or
19 (iii) the consulting medical staff committee and ambulatory
20 surgical treatment center in order to provide services. The
21 medical staff, physician committee, or consulting medical
22 staff committee shall periodically review the services of
23 physician assistants granted clinical privileges, including
24 any care provided in a hospital affiliate or federally
25 qualified health center. A physician assistant practicing

1 under this Section may prescribe, select, order, and
2 administer medications, including controlled substances.
3 ~~Authority may also be granted when recommended by the hospital~~
4 ~~medical staff and granted by the hospital, recommended by the~~
5 ~~physician committee and granted by the federally qualified~~
6 ~~health center, or recommended by the consulting medical staff~~
7 ~~committee and ambulatory surgical treatment center to~~
8 ~~individual physician assistants to select, order, and~~
9 ~~administer medications, including controlled substances, to~~
10 ~~provide delineated care.~~ In a hospital, hospital affiliate,
11 federally qualified health center, or ambulatory surgical
12 treatment center, the attending physician shall determine a
13 physician assistant's role in providing care for his or her
14 patients, except as otherwise provided in the medical staff
15 bylaws or consulting committee policies.

16 (a-5) Physician assistants practicing in a hospital
17 affiliate or a federally qualified health center may ~~be, but~~
18 ~~are not required to be, granted authority to~~ prescribe
19 Schedule II through V controlled substances ~~when such~~
20 ~~authority is recommended by the appropriate physician~~
21 ~~committee of the hospital affiliate and granted by the~~
22 ~~hospital affiliate or recommended by the physician committee~~
23 ~~of the federally qualified health center and granted by the~~
24 ~~federally qualified health center.~~ This authority may, ~~but is~~
25 ~~not required to,~~ include prescription of, selection of, orders
26 for, administration of, storage of, acceptance of samples of,

1 and dispensing over-the-counter medications, legend drugs,
2 medical gases, and controlled substances categorized as
3 Schedule II through V controlled substances, as defined in
4 Article II of the Illinois Controlled Substances Act, and
5 other preparations, including, but not limited to, botanical
6 and herbal remedies.

7 To prescribe controlled substances under this subsection
8 (a-5), a physician assistant must obtain a mid-level
9 practitioner controlled substance license. ~~Medication orders~~
10 ~~shall be reviewed periodically by the appropriate hospital~~
11 ~~affiliate physicians committee or its physician designee or by~~
12 ~~the physician committee of a federally qualified health~~
13 ~~center.~~

14 ~~The hospital affiliate or federally qualified health~~
15 ~~center shall file with the Department notice of a grant of~~
16 ~~prescriptive authority consistent with this subsection (a 5)~~
17 ~~and termination of such a grant of authority in accordance~~
18 ~~with rules of the Department. Upon receipt of this notice of~~
19 ~~grant of authority to prescribe any Schedule II through V~~
20 ~~controlled substances, the licensed physician assistant may~~
21 ~~register for a mid-level practitioner controlled substance~~
22 ~~license under Section 303.05 of the Illinois Controlled~~
23 ~~Substances Act.~~

24 ~~In addition, a hospital affiliate or a federally qualified~~
25 ~~health center may, but is not required to, grant authority to a~~
26 ~~physician assistant to prescribe any Schedule II controlled~~

1 ~~substances if all of the following conditions apply:~~

2 ~~(1) specific Schedule II controlled substances by oral~~
3 ~~dosage or topical or transdermal application may be~~
4 ~~designated, provided that the designated Schedule II~~
5 ~~controlled substances are routinely prescribed by~~
6 ~~physician assistants in their area of certification; this~~
7 ~~grant of authority must identify the specific Schedule II~~
8 ~~controlled substances by either brand name or generic~~
9 ~~name; authority to prescribe or dispense Schedule II~~
10 ~~controlled substances to be delivered by injection or~~
11 ~~other route of administration may not be granted;~~

12 ~~(2) any grant of authority must be controlled~~
13 ~~substances limited to the practice of the physician~~
14 ~~assistant;~~

15 ~~(3) any prescription must be limited to no more than a~~
16 ~~30 day supply;~~

17 ~~(4) the physician assistant must discuss the condition~~
18 ~~of any patients for whom a controlled substance is~~
19 ~~prescribed monthly with the appropriate physician~~
20 ~~committee of the hospital affiliate or its physician~~
21 ~~designee, or the physician committee of a federally~~
22 ~~qualified health center; and~~

23 ~~(5) the physician assistant must meet the education~~
24 ~~requirements of Section 303.05 of the Illinois Controlled~~
25 ~~Substances Act.~~

26 (b) A physician assistant ~~granted authority to order~~

1 ~~medications including controlled substances~~ may complete
2 discharge prescriptions provided the prescription is in the
3 name of the physician assistant ~~and the attending or~~
4 ~~discharging physician.~~

5 (c) Physician assistants practicing in a hospital,
6 hospital affiliate, federally qualified health center, or an
7 ambulatory surgical treatment center are not required to
8 obtain a mid-level controlled substance license to order
9 controlled substances under Section 303.05 of the Illinois
10 Controlled Substances Act.

11 (d) Delegation of prescriptive authority by a physician is
12 not required under this Section.

13 (Source: P.A. 103-65, eff. 1-1-24.)

14 (225 ILCS 95/7.8 new)

15 Sec. 7.8. Prescriptive authority. A physician assistant
16 may prescribe, dispense, order, administer, and procure drugs
17 and medical devices without delegation of authority by a
18 physician. The prescriptive authority may include prescribing
19 Schedule II, III, IV, and V controlled substances. To
20 prescribe Schedule II, III, IV, or V controlled substances
21 under this Act, a physician assistant must obtain a mid-level
22 practitioner controlled substances license. When a written
23 collaborative agreement is required under this Act, delegation
24 of prescriptive authority by a physician is not required.

1 (225 ILCS 95/7.9 new)

2 Sec. 7.9. Optimal practice authority.

3 (a) A physician assistant licensed under this Act shall be
4 deemed by law to possess the ability to practice without a
5 written collaborative agreement upon meeting the requirements
6 of this Section.

7 (b) A physician assistant who files with the Department a
8 notarized attestation of completion of at least 6,000 hours of
9 postgraduate clinical experience after initial certification
10 and at least 250 hours of continuing education or training
11 shall not require a written collaborative agreement.
12 Documentation of successful completion shall be provided to
13 the Department upon request. The clinical experience shall be
14 completed in collaboration with a physician or physicians.
15 Completion of the clinical experience must be attested to by
16 the collaborating physician, employer, or other evidence as
17 established by Department rule.

18 (c) A physician assistant, with optimal practice
19 authority, may practice in all settings consistent with the
20 physician assistant's education, training, and experience, and
21 in accordance with applicable State and federal laws governing
22 prescriptive authority, and the practice of medicine.

23 (d) A physician assistant exercising prescriptive
24 authority under optimal practice authority shall complete 80
25 hours of continuing education for every 2-year license renewal
26 cycle. The 80 hours of continuing education required under

1 this subsection shall be completed as follows:

2 (1) A minimum of 50 hours of continuing education
3 shall be obtained in continuing education programs as
4 determined by Department rule and shall include no less
5 than 20 hours of pharmacotherapeutics, including at least
6 10 hours related to opioid prescribing, substance use
7 disorders, and safe prescribing. Continuing education
8 programs shall be relevant to physician assistant practice
9 and may be conducted or endorsed by educational
10 institutions, hospitals, professional associations, or
11 other organizations approved to offer continuing education
12 under this Act or rules.

13 (2) A maximum of 30 hours of credit may be obtained
14 through presentations in the physician assistant's
15 clinical specialty, evidence-based practice, quality
16 improvement projects, publications, research projects, or
17 preceptor hours, as determined by Department rule.

18 The rules adopted regarding continuing education shall be
19 consistent, to the extent possible, with requirements of
20 relevant national certifying bodies or State or national
21 professional associations.

22 The rules shall provide for variances in part or in whole
23 for good cause, including, but not limited to, illness or
24 hardship.

25 Each physician assistant is responsible for maintaining
26 records of completion of continuing education and shall be

1 prepared to produce the records when requested by the
2 Department.

3 (e) A physician assistant with optimal practice authority
4 may prescribe Schedule II narcotic drugs only in a
5 consultation relationship with a physician. The consultation
6 relationship shall be recorded on the Prescription Monitoring
7 Program website, pursuant to Section 316 of the Illinois
8 Controlled Substances Act, by the physician and physician
9 assistant with optimal practice authority, and is not required
10 to be filed with the Department.

11 The specific Schedule II narcotic drug must be identified
12 by either brand name or generic name. The specific Schedule II
13 narcotic drug, such as an opioid, may be administered by oral
14 dosage or topical or transdermal application. Delivery by
15 injection or other route of administration is not permitted.
16 At least monthly, the physician assistant with optimal
17 practice authority and the physician must discuss the
18 condition of any patients for whom a Schedule II narcotic drug
19 is prescribed.

20 Nothing in this subsection shall be construed to require a
21 prescription by a physician assistant with optimal practice
22 authority to include a physician name.

23 The consultation relationship shall provide for physician
24 availability for consultation on complex clinical cases and
25 prescribing decisions, but shall not require the physical
26 presence of the physician or constitute a written

1 collaborative agreement. Documentation of the consultation
2 relationship shall be maintained and made available to the
3 Department upon request.

4 (f) The Department may adopt any rules necessary to
5 administer this Section.

6 (225 ILCS 95/7.10 new)

7 Sec. 7.10. National certification requirement. A physician
8 assistant with optimal practice authority shall maintain
9 current national certification from a nationally recognized
10 certifying body as a condition of licensure and practice.

11 (225 ILCS 95/21) (from Ch. 111, par. 4621)

12 (Section scheduled to be repealed on January 1, 2028)

13 Sec. 21. Grounds for disciplinary action.

14 (a) The Department may refuse to issue or to renew, or may
15 revoke, suspend, place on probation, reprimand, or take other
16 disciplinary or non-disciplinary action with regard to any
17 license issued under this Act as the Department may deem
18 proper, including the issuance of fines not to exceed \$10,000
19 for each violation, for any one or combination of the
20 following causes:

21 (1) Material misstatement in furnishing information to
22 the Department.

23 (2) Violations of this Act, or the rules adopted under
24 this Act.

1 (3) Conviction by plea of guilty or nolo contendere,
2 finding of guilt, jury verdict, or entry of judgment or
3 sentencing, including, but not limited to, convictions,
4 preceding sentences of supervision, conditional discharge,
5 or first offender probation, under the laws of any
6 jurisdiction of the United States that is: (i) a felony;
7 or (ii) a misdemeanor, an essential element of which is
8 dishonesty, or that is directly related to the practice of
9 the profession.

10 (4) Making any misrepresentation for the purpose of
11 obtaining licenses.

12 (5) Professional incompetence.

13 (6) Aiding or assisting another person in violating
14 any provision of this Act or its rules.

15 (7) Failing, within 60 days, to provide information in
16 response to a written request made by the Department.

17 (8) Engaging in dishonorable, unethical, or
18 unprofessional conduct, as defined by rule, of a character
19 likely to deceive, defraud, or harm the public.

20 (9) Habitual or excessive use or addiction to alcohol,
21 narcotics, stimulants, or any other chemical agent or drug
22 that results in a physician assistant's inability to
23 practice with reasonable judgment, skill, or safety.

24 (10) Discipline by another U.S. jurisdiction or
25 foreign nation, if at least one of the grounds for
26 discipline is the same or substantially equivalent to

1 those set forth in this Section.

2 (11) Directly or indirectly giving to or receiving
3 from any person, firm, corporation, partnership, or
4 association any fee, commission, rebate, or other form of
5 compensation for any professional services not actually or
6 personally rendered. Nothing in this paragraph (11)
7 affects any bona fide independent contractor or employment
8 arrangements, which may include provisions for
9 compensation, health insurance, pension, or other
10 employment benefits, with persons or entities authorized
11 under this Act for the provision of services within the
12 scope of the licensee's practice under this Act.

13 (12) A finding by the Board that the licensee, after
14 having his or her license placed on probationary status,
15 has violated the terms of probation.

16 (13) Abandonment of a patient.

17 (14) Willfully making or filing false records or
18 reports in his or her practice, including, but not limited
19 to, false records filed with State agencies or
20 departments.

21 (15) Willfully failing to report an instance of
22 suspected child abuse or neglect as required by the Abused
23 and Neglected Child Reporting Act.

24 (16) Physical illness, or mental illness or impairment
25 that results in the inability to practice the profession
26 with reasonable judgment, skill, or safety, including, but

1 not limited to, deterioration through the aging process or
2 loss of motor skill.

3 (17) Being named as a perpetrator in an indicated
4 report by the Department of Children and Family Services
5 under the Abused and Neglected Child Reporting Act, and
6 upon proof by clear and convincing evidence that the
7 licensee has caused a child to be an abused child or
8 neglected child as defined in the Abused and Neglected
9 Child Reporting Act.

10 (18) (Blank).

11 (19) Gross negligence resulting in permanent injury or
12 death of a patient.

13 (20) Employment of fraud, deception or any unlawful
14 means in applying for or securing a license as a physician
15 assistant.

16 (21) Exceeding the authority delegated to him or her
17 by his or her collaborating physician in a written
18 collaborative agreement, when the agreement is required
19 under this Act.

20 (22) Immoral conduct in the commission of any act,
21 such as sexual abuse, sexual misconduct, or sexual
22 exploitation related to the licensee's practice.

23 (23) Violation of the Health Care Worker Self-Referral
24 Act.

25 (24) Practicing under a false or assumed name, except
26 as provided by law.

1 (25) Making a false or misleading statement regarding
2 his or her skill or the efficacy or value of the medicine,
3 treatment, or remedy prescribed by him or her in the
4 course of treatment.

5 (26) Allowing another person to use his or her license
6 to practice.

7 (27) Prescribing, selling, administering,
8 distributing, giving, or self-administering a drug
9 classified as a controlled substance for other than
10 medically accepted therapeutic purposes.

11 (28) Promotion of the sale of drugs, devices,
12 appliances, or goods provided for a patient in a manner to
13 exploit the patient for financial gain.

14 (29) A pattern of practice or other behavior that
15 demonstrates incapacity or incompetence to practice under
16 this Act.

17 (30) Violating State or federal laws or regulations
18 relating to controlled substances or other legend drugs or
19 ephedra as defined in the Ephedra Prohibition Act.

20 (31) (Blank). ~~Exceeding the prescriptive authority~~
21 ~~delegated by the collaborating physician or violating the~~
22 ~~written collaborative agreement delegating that authority.~~

23 (32) (Blank). ~~Practicing without providing to the~~
24 ~~Department a notice of collaboration or delegation of~~
25 ~~prescriptive authority.~~

26 (33) Failure to establish and maintain records of

1 patient care and treatment as required by law.

2 (34) Attempting to subvert or cheat on the examination
3 of the National Commission on Certification of Physician
4 Assistants or its successor agency.

5 (35) Willfully or negligently violating the
6 confidentiality between physician assistant and patient,
7 except as required by law.

8 (36) Willfully failing to report an instance of
9 suspected abuse, neglect, financial exploitation, or
10 self-neglect of an eligible adult as defined in and
11 required by the Adult Protective Services Act.

12 (37) Being named as an abuser in a verified report by
13 the Department on Aging under the Adult Protective
14 Services Act and upon proof by clear and convincing
15 evidence that the licensee abused, neglected, or
16 financially exploited an eligible adult as defined in the
17 Adult Protective Services Act.

18 (38) Failure to report to the Department an adverse
19 final action taken against him or her by another licensing
20 jurisdiction of the United States or a foreign state or
21 country, a peer review body, a health care institution, a
22 professional society or association, a governmental
23 agency, a law enforcement agency, or a court acts or
24 conduct similar to acts or conduct that would constitute
25 grounds for action under this Section.

26 (39) Failure to provide copies of records of patient

1 care or treatment, except as required by law.

2 (40) (Blank). ~~Entering into an excessive number of~~
3 ~~written collaborative agreements with licensed physicians~~
4 ~~resulting in an inability to adequately collaborate.~~

5 (41) (Blank). ~~Repeated failure to adequately~~
6 ~~collaborate with a collaborating physician.~~

7 (42) Violating the Compassionate Use of Medical
8 Cannabis Program Act.

9 (b) The Department may, without a hearing, refuse to issue
10 or renew or may suspend the license of any person who fails to
11 file a return, or to pay the tax, penalty, or interest shown in
12 a filed return, or to pay any final assessment of the tax,
13 penalty, or interest as required by any tax Act administered
14 by the Illinois Department of Revenue, until such time as the
15 requirements of any such tax Act are satisfied.

16 (b-5) The Department shall not revoke, suspend, summarily
17 suspend, place on prohibition, reprimand, refuse to issue or
18 renew, or take any other disciplinary or non-disciplinary
19 action against a person's authorization to practice under this
20 Act based solely upon the person providing, authorizing,
21 recommending, aiding, assisting, referring for, or otherwise
22 participating in any health care service, so long as the care
23 was not unlawful under the laws of this State, regardless of
24 whether the patient was a resident of this State or another
25 state.

26 (b-10) The Department shall not revoke, suspend, summarily

1 suspend, place on prohibition, reprimand, refuse to issue or
2 renew, or take any other disciplinary or non-disciplinary
3 action against a person's authorization to practice under this
4 Act based upon the person's license, registration, or permit
5 being revoked or suspended, or the person being otherwise
6 disciplined, by any other state if that revocation,
7 suspension, or other form of discipline was based solely on
8 the person violating another state's laws prohibiting the
9 provision of, authorization of, recommendation of, aiding or
10 assisting in, referring for, or participation in any health
11 care service if that health care service as provided would not
12 have been unlawful under the laws of this State and is
13 consistent with the applicable standard of conduct for a
14 person practicing in Illinois under this Act.

15 (b-15) The conduct specified in subsections (b-5) and
16 (b-10) shall not constitute grounds for suspension under
17 Section 22.13.

18 (b-20) An applicant seeking licensure, certification, or
19 authorization pursuant to this Act who has been subject to
20 disciplinary action by a duly authorized professional
21 disciplinary agency of another jurisdiction solely on the
22 basis of having provided, authorized, recommended, aided,
23 assisted, referred for, or otherwise participated in health
24 care shall not be denied such licensure, certification, or
25 authorization, unless the Department determines that such
26 action would have constituted professional misconduct in this

1 State; however, nothing in this Section shall be construed as
2 prohibiting the Department from evaluating the conduct of such
3 applicant and making a determination regarding the licensure,
4 certification, or authorization to practice a profession under
5 this Act.

6 (c) The determination by a circuit court that a licensee
7 is subject to involuntary admission or judicial admission as
8 provided in the Mental Health and Developmental Disabilities
9 Code operates as an automatic suspension. The suspension will
10 end only upon a finding by a court that the patient is no
11 longer subject to involuntary admission or judicial admission
12 and issues an order so finding and discharging the patient,
13 and upon the recommendation of the Board to the Secretary that
14 the licensee be allowed to resume his or her practice.

15 (d) In enforcing this Section, the Department upon a
16 showing of a possible violation may compel an individual
17 licensed to practice under this Act, or who has applied for
18 licensure under this Act, to submit to a mental or physical
19 examination, or both, which may include a substance abuse or
20 sexual offender evaluation, as required by and at the expense
21 of the Department.

22 The Department shall specifically designate the examining
23 physician licensed to practice medicine in all of its branches
24 or, if applicable, the multidisciplinary team involved in
25 providing the mental or physical examination or both. The
26 multidisciplinary team shall be led by a physician licensed to

1 practice medicine in all of its branches and may consist of one
2 or more or a combination of physicians licensed to practice
3 medicine in all of its branches, licensed clinical
4 psychologists, licensed clinical social workers, licensed
5 clinical professional counselors, and other professional and
6 administrative staff. Any examining physician or member of the
7 multidisciplinary team may require any person ordered to
8 submit to an examination pursuant to this Section to submit to
9 any additional supplemental testing deemed necessary to
10 complete any examination or evaluation process, including, but
11 not limited to, blood testing, urinalysis, psychological
12 testing, or neuropsychological testing.

13 The Department may order the examining physician or any
14 member of the multidisciplinary team to provide to the
15 Department any and all records, including business records,
16 that relate to the examination and evaluation, including any
17 supplemental testing performed.

18 The Department may order the examining physician or any
19 member of the multidisciplinary team to present testimony
20 concerning the mental or physical examination of the licensee
21 or applicant. No information, report, record, or other
22 documents in any way related to the examination shall be
23 excluded by reason of any common law or statutory privilege
24 relating to communications between the licensee or applicant
25 and the examining physician or any member of the
26 multidisciplinary team. No authorization is necessary from the

1 licensee or applicant ordered to undergo an examination for
2 the examining physician or any member of the multidisciplinary
3 team to provide information, reports, records, or other
4 documents or to provide any testimony regarding the
5 examination and evaluation.

6 The individual to be examined may have, at his or her own
7 expense, another physician of his or her choice present during
8 all aspects of this examination. However, that physician shall
9 be present only to observe and may not interfere in any way
10 with the examination.

11 Failure of an individual to submit to a mental or physical
12 examination, when ordered, shall result in an automatic
13 suspension of his or her license until the individual submits
14 to the examination.

15 If the Department finds an individual unable to practice
16 because of the reasons set forth in this Section, the
17 Department may require that individual to submit to care,
18 counseling, or treatment by physicians approved or designated
19 by the Department, as a condition, term, or restriction for
20 continued, reinstated, or renewed licensure to practice; or,
21 in lieu of care, counseling, or treatment, the Department may
22 file a complaint to immediately suspend, revoke, or otherwise
23 discipline the license of the individual. An individual whose
24 license was granted, continued, reinstated, renewed,
25 disciplined, or supervised subject to such terms, conditions,
26 or restrictions, and who fails to comply with such terms,

1 conditions, or restrictions, shall be referred to the
2 Secretary for a determination as to whether the individual
3 shall have his or her license suspended immediately, pending a
4 hearing by the Department.

5 In instances in which the Secretary immediately suspends a
6 person's license under this Section, a hearing on that
7 person's license must be convened by the Department within 30
8 days after the suspension and completed without appreciable
9 delay. The Department shall have the authority to review the
10 subject individual's record of treatment and counseling
11 regarding the impairment to the extent permitted by applicable
12 federal statutes and regulations safeguarding the
13 confidentiality of medical records.

14 An individual licensed under this Act and affected under
15 this Section shall be afforded an opportunity to demonstrate
16 to the Department that he or she can resume practice in
17 compliance with acceptable and prevailing standards under the
18 provisions of his or her license.

19 (e) An individual or organization acting in good faith,
20 and not in a willful and wanton manner, in complying with this
21 Section by providing a report or other information to the
22 Board, by assisting in the investigation or preparation of a
23 report or information, by participating in proceedings of the
24 Board, or by serving as a member of the Board, shall not be
25 subject to criminal prosecution or civil damages as a result
26 of such actions.

1 (f) Members of the Board shall be indemnified by the State
2 for any actions occurring within the scope of services on the
3 Board, done in good faith and not willful and wanton in nature.
4 The Attorney General shall defend all such actions unless he
5 or she determines either that there would be a conflict of
6 interest in such representation or that the actions complained
7 of were not in good faith or were willful and wanton.

8 If the Attorney General declines representation, the
9 member has the right to employ counsel of his or her choice,
10 whose fees shall be provided by the State, after approval by
11 the Attorney General, unless there is a determination by a
12 court that the member's actions were not in good faith or were
13 willful and wanton.

14 The member must notify the Attorney General within 7 days
15 after receipt of notice of the initiation of any action
16 involving services of the Board. Failure to so notify the
17 Attorney General constitutes an absolute waiver of the right
18 to a defense and indemnification.

19 The Attorney General shall determine, within 7 days after
20 receiving such notice, whether he or she will undertake to
21 represent the member.

22 (g) The Department may adopt rules to implement,
23 administer, and enforce this Section.

24 (Source: P.A. 104-432, eff. 1-1-26.)

25 Section 10. The Illinois Controlled Substances Act is

1 amended by changing Sections 102 and 303.05 as follows:

2 (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102)

3 Sec. 102. Definitions. As used in this Act, unless the
4 context otherwise requires:

5 (a) "Person with a substance use disorder" means any
6 person who has a substance use disorder diagnosis defined as a
7 spectrum of persistent and recurring problematic behavior that
8 encompasses 10 separate classes of drugs: alcohol; caffeine;
9 cannabis; hallucinogens; inhalants; opioids; sedatives,
10 hypnotics and anxiolytics; stimulants; and tobacco; and other
11 unknown substances leading to clinically significant
12 impairment or distress.

13 (b) "Administer" means the direct application of a
14 controlled substance, whether by injection, inhalation,
15 ingestion, or any other means, to the body of a patient,
16 research subject, or animal (as defined by the Humane
17 Euthanasia in Animal Shelters Act) by:

18 (1) a practitioner (or, in his or her presence, by his
19 or her authorized agent),

20 (2) the patient or research subject pursuant to an
21 order, or

22 (3) a euthanasia technician as defined by the Humane
23 Euthanasia in Animal Shelters Act.

24 (c) "Agent" means an authorized person who acts on behalf
25 of or at the direction of a manufacturer, distributor,

1 dispenser, prescriber, or practitioner. It does not include a
2 common or contract carrier, public warehouseman or employee of
3 the carrier or warehouseman.

4 (c-1) "Anabolic Steroids" means any drug or hormonal
5 substance, chemically and pharmacologically related to
6 testosterone (other than estrogens, progestins,
7 corticosteroids, and dehydroepiandrosterone), and includes:

8 (i) 3[beta],17-dihydroxy-5a-androstane,

9 (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane,

10 (iii) 5[alpha]-androstane-3,17-dione,

11 (iv) 1-androstenediol (3[beta],

12 17[beta]-dihydroxy-5[alpha]-androst-1-ene),

13 (v) 1-androstenediol (3[alpha],

14 17[beta]-dihydroxy-5[alpha]-androst-1-ene),

15 (vi) 4-androstenediol

16 (3[beta],17[beta]-dihydroxy-androst-4-ene),

17 (vii) 5-androstenediol

18 (3[beta],17[beta]-dihydroxy-androst-5-ene),

19 (viii) 1-androstenedione

20 ([5alpha]-androst-1-en-3,17-dione),

21 (ix) 4-androstenedione

22 (androst-4-en-3,17-dione),

23 (x) 5-androstenedione

24 (androst-5-en-3,17-dione),

25 (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]-

26 hydroxyandrost-4-en-3-one),

- 1 (xii) boldenone (17[beta]-hydroxyandrost-
2 1,4,-diene-3-one),
3 (xiii) boldione (androsta-1,4-
4 diene-3,17-dione),
5 (xiv) calusterone (7[beta],17[alpha]-dimethyl-17
6 [beta]-hydroxyandrost-4-en-3-one),
7 (xv) clostebol (4-chloro-17[beta]-
8 hydroxyandrost-4-en-3-one),
9 (xvi) dehydrochloromethyltestosterone (4-chloro-
10 17[beta]-hydroxy-17[alpha]-methyl-
11 androst-1,4-dien-3-one),
12 (xvii) desoxymethyltestosterone
13 (17[alpha]-methyl-5[alpha]
14 -androst-2-en-17[beta]-ol) (a.k.a., madol),
15 (xviii) [delta]1-dihydrotestosterone (a.k.a.
16 '1-testosterone') (17[beta]-hydroxy-
17 5[alpha]-androst-1-en-3-one),
18 (xix) 4-dihydrotestosterone (17[beta]-hydroxy-
19 androstan-3-one),
20 (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl-
21 5[alpha]-androstan-3-one),
22 (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-
23 hydroxyestr-4-ene),
24 (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl-
25 1[beta],17[beta]-dihydroxyandrost-4-en-3-one),
26 (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha],

1 17[beta]-dihydroxyandrost-1,4-dien-3-one),
2 (xxiv) furazabol (17[alpha]-methyl-17[beta]-
3 hydroxyandrostano[2,3-c]-furazan),
4 (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one,
5 (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy-
6 androst-4-en-3-one),
7 (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]-
8 dihydroxy-estr-4-en-3-one),
9 (xxviii) mestanolone (17[alpha]-methyl-17[beta]-
10 hydroxy-5-androstan-3-one),
11 (xxix) mesterolone (1-methyl-17[beta]-hydroxy-
12 [5a]-androstan-3-one),
13 (xxx) methandienone (17[alpha]-methyl-17[beta]-
14 hydroxyandrost-1,4-dien-3-one),
15 (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]-
16 dihydroxyandrost-5-ene),
17 (xxxii) methenolone (1-methyl-17[beta]-hydroxy-
18 5[alpha]-androst-1-en-3-one),
19 (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]-
20 dihydroxy-5a-androstane,
21 (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy
22 -5a-androstane,
23 (xxxv) 17[alpha]-methyl-3[beta],17[beta]-
24 dihydroxyandrost-4-ene),
25 (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-
26 methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one),

- 1 (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-
2 hydroxyestra-4,9(10)-dien-3-one),
3 (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-
4 hydroxyestra-4,9-11-trien-3-one),
5 (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-
6 hydroxyandrost-4-en-3-one),
7 (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]-
8 hydroxyestr-4-en-3-one),
9 (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone
10 (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]-
11 androst-1-en-3-one) (a.k.a. '17-[alpha]-methyl-
12 1-testosterone'),
13 (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one),
14 (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]-
15 dihydroxyestr-4-ene),
16 (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]-
17 dihydroxyestr-4-ene),
18 (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]-
19 dihydroxyestr-5-ene),
20 (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]-
21 dihydroxyestr-5-ene),
22 (xlvii) 19-nor-4,9(10)-androstadienedione
23 (estra-4,9(10)-diene-3,17-dione),
24 (xlviii) 19-nor-4-androstenedione (estr-4-
25 en-3,17-dione),
26 (xlix) 19-nor-5-androstenedione (estr-5-

1 en-3,17-dione),
2 (l) norbolethone (13[beta], 17a-diethyl-17[beta]-
3 hydroxygon-4-en-3-one),
4 (li) norclostebol (4-chloro-17[beta]-
5 hydroxyestr-4-en-3-one),
6 (lii) norethandrolone (17[alpha]-ethyl-17[beta]-
7 hydroxyestr-4-en-3-one),
8 (liii) normethandrolone (17[alpha]-methyl-17[beta]-
9 hydroxyestr-4-en-3-one),
10 (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-
11 2-oxa-5[alpha]-androstan-3-one),
12 (lv) oxymesterone (17[alpha]-methyl-4,17[beta]-
13 dihydroxyandrost-4-en-3-one),
14 (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-
15 17[beta]-hydroxy-(5[alpha]-androstan-3-one),
16 (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy-
17 (5[alpha]-androst-2-eno[3,2-c]-pyrazole),
18 (lviii) stenbolone (17[beta]-hydroxy-2-methyl-
19 (5[alpha]-androst-1-en-3-one),
20 (lix) testolactone (13-hydroxy-3-oxo-13,17-
21 secoandrosta-1,4-dien-17-oic
22 acid lactone),
23 (lx) testosterone (17[beta]-hydroxyandrost-
24 4-en-3-one),
25 (lxi) tetrahydrogestrinone (13[beta], 17[alpha]-
26 diethyl-17[beta]-hydroxygon-

1 4,9,11-trien-3-one),
2 (lxii) trenbolone (17[beta]-hydroxyestr-4,9,
3 11-trien-3-one).

4 Any person who is otherwise lawfully in possession of an
5 anabolic steroid, or who otherwise lawfully manufactures,
6 distributes, dispenses, delivers, or possesses with intent to
7 deliver an anabolic steroid, which anabolic steroid is
8 expressly intended for and lawfully allowed to be administered
9 through implants to livestock or other nonhuman species, and
10 which is approved by the Secretary of Health and Human
11 Services for such administration, and which the person intends
12 to administer or have administered through such implants,
13 shall not be considered to be in unauthorized possession or to
14 unlawfully manufacture, distribute, dispense, deliver, or
15 possess with intent to deliver such anabolic steroid for
16 purposes of this Act.

17 (d) "Administration" means the Drug Enforcement
18 Administration, United States Department of Justice, or its
19 successor agency.

20 (d-5) "Clinical Director, Prescription Monitoring Program"
21 means a Department of Human Services administrative employee
22 licensed to either prescribe or dispense controlled substances
23 who shall run the clinical aspects of the Department of Human
24 Services Prescription Monitoring Program and its Prescription
25 Information Library.

26 (d-10) "Compounding" means the preparation and mixing of

1 components, excluding flavorings, (1) as the result of a
2 prescriber's prescription drug order or initiative based on
3 the prescriber-patient-pharmacist relationship in the course
4 of professional practice or (2) for the purpose of, or
5 incident to, research, teaching, or chemical analysis and not
6 for sale or dispensing. "Compounding" includes the preparation
7 of drugs or devices in anticipation of receiving prescription
8 drug orders based on routine, regularly observed dispensing
9 patterns. Commercially available products may be compounded
10 for dispensing to individual patients only if both of the
11 following conditions are met: (i) the commercial product is
12 not reasonably available from normal distribution channels in
13 a timely manner to meet the patient's needs and (ii) the
14 prescribing practitioner has requested that the drug be
15 compounded.

16 (e) "Control" means to add a drug or other substance, or
17 immediate precursor, to a Schedule whether by transfer from
18 another Schedule or otherwise.

19 (f) "Controlled Substance" means (i) a drug, substance,
20 immediate precursor, or synthetic drug in the Schedules of
21 Article II of this Act or (ii) a drug or other substance, or
22 immediate precursor, designated as a controlled substance by
23 the Department through administrative rule. The term does not
24 include distilled spirits, wine, malt beverages, or tobacco,
25 as those terms are defined or used in the Liquor Control Act of
26 1934 and the Tobacco Products Tax Act of 1995.

1 (f-5) "Controlled substance analog" means a substance:

2 (1) the chemical structure of which is substantially
3 similar to the chemical structure of a controlled
4 substance in Schedule I or II;

5 (2) which has a stimulant, depressant, or
6 hallucinogenic effect on the central nervous system that
7 is substantially similar to or greater than the stimulant,
8 depressant, or hallucinogenic effect on the central
9 nervous system of a controlled substance in Schedule I or
10 II; or

11 (3) with respect to a particular person, which such
12 person represents or intends to have a stimulant,
13 depressant, or hallucinogenic effect on the central
14 nervous system that is substantially similar to or greater
15 than the stimulant, depressant, or hallucinogenic effect
16 on the central nervous system of a controlled substance in
17 Schedule I or II.

18 (g) "Counterfeit substance" means a controlled substance,
19 which, or the container or labeling of which, without
20 authorization bears the trademark, trade name, or other
21 identifying mark, imprint, number or device, or any likeness
22 thereof, of a manufacturer, distributor, or dispenser other
23 than the person who in fact manufactured, distributed, or
24 dispensed the substance.

25 (h) "Deliver" or "delivery" means the actual, constructive
26 or attempted transfer of possession of a controlled substance,

1 with or without consideration, whether or not there is an
2 agency relationship. "Deliver" or "delivery" does not include
3 the donation of drugs to the extent permitted under the
4 Illinois Drug Reuse Opportunity Program Act.

5 (i) "Department" means the Illinois Department of Human
6 Services (as successor to the Department of Alcoholism and
7 Substance Abuse) or its successor agency.

8 (j) (Blank).

9 (k) "Department of Corrections" means the Department of
10 Corrections of the State of Illinois or its successor agency.

11 (l) "Department of Financial and Professional Regulation"
12 means the Department of Financial and Professional Regulation
13 of the State of Illinois or its successor agency.

14 (m) "Depressant" means any drug that (i) causes an overall
15 depression of central nervous system functions, (ii) causes
16 impaired consciousness and awareness, and (iii) can be
17 habit-forming or lead to a substance misuse or substance use
18 disorder, including, but not limited to, alcohol, cannabis and
19 its active principles and their analogs, benzodiazepines and
20 their analogs, barbiturates and their analogs, opioids
21 (natural and synthetic) and their analogs, and chloral hydrate
22 and similar sedative hypnotics.

23 (n) (Blank).

24 (o) "Director" means the Director of the Illinois State
25 Police or his or her designated agents.

26 (p) "Dispense" means to deliver a controlled substance to

1 an ultimate user or research subject by or pursuant to the
2 lawful order of a prescriber, including the prescribing,
3 administering, packaging, labeling, or compounding necessary
4 to prepare the substance for that delivery.

5 (q) "Dispenser" means a practitioner who dispenses.

6 (r) "Distribute" means to deliver, other than by
7 administering or dispensing, a controlled substance.

8 (s) "Distributor" means a person who distributes.

9 (t) "Drug" means (1) substances recognized as drugs in the
10 official United States Pharmacopoeia, Official Homeopathic
11 Pharmacopoeia of the United States, or official National
12 Formulary, or any supplement to any of them; (2) substances
13 intended for use in diagnosis, cure, mitigation, treatment, or
14 prevention of disease in man or animals; (3) substances (other
15 than food) intended to affect the structure of any function of
16 the body of man or animals and (4) substances intended for use
17 as a component of any article specified in clause (1), (2), or
18 (3) of this subsection. It does not include devices or their
19 components, parts, or accessories.

20 (t-3) "Electronic health record" or "EHR" means an
21 electronic record of health-related information on an
22 individual that is created, gathered, managed, and consulted
23 by authorized health care clinicians and staff.

24 (t-3.5) "Electronic health record system" or "EHR system"
25 means any computer-based system or combination of federally
26 certified Health IT Modules (defined at 42 CFR 170.102 or its

1 successor) used as a repository for electronic health records
2 and accessed or updated by a prescriber or authorized
3 surrogate in the ordinary course of his or her medical
4 practice. For purposes of connecting to the Prescription
5 Information Library maintained by the Bureau of Pharmacy and
6 Clinical Support Systems or its successor, an EHR system may
7 connect to the Prescription Information Library directly or
8 through all or part of a computer program or system that is a
9 federally certified Health IT Module maintained by a third
10 party and used by the EHR system to secure access to the
11 database.

12 (t-4) "Emergency medical services personnel" has the
13 meaning ascribed to it in the Emergency Medical Services (EMS)
14 Systems Act.

15 (t-5) "Euthanasia agency" means an entity certified by the
16 Department of Financial and Professional Regulation for the
17 purpose of animal euthanasia that holds an animal control
18 facility license or animal shelter license under the Animal
19 Welfare Act. A euthanasia agency is authorized to purchase,
20 store, possess, and utilize Schedule II nonnarcotic and
21 Schedule III nonnarcotic drugs for the sole purpose of animal
22 euthanasia.

23 (t-10) "Euthanasia drugs" means Schedule II or Schedule
24 III substances (nonnarcotic controlled substances) that are
25 used by a euthanasia agency for the purpose of animal
26 euthanasia.

1 (u) "Good faith" means the prescribing or dispensing of a
2 controlled substance by a practitioner in the regular course
3 of professional treatment to or for any person who is under his
4 or her treatment for a pathology or condition other than that
5 individual's physical or psychological dependence upon a
6 controlled substance, except as provided herein: and
7 application of the term to a pharmacist shall mean the
8 dispensing of a controlled substance pursuant to the
9 prescriber's order which in the professional judgment of the
10 pharmacist is lawful. The pharmacist shall be guided by
11 accepted professional standards, including, but not limited
12 to, the following, in making the judgment:

13 (1) lack of consistency of prescriber-patient
14 relationship,

15 (2) frequency of prescriptions for same drug by one
16 prescriber for large numbers of patients,

17 (3) quantities beyond those normally prescribed,

18 (4) unusual dosages (recognizing that there may be
19 clinical circumstances where more or less than the usual
20 dose may be used legitimately),

21 (5) unusual geographic distances between patient,
22 pharmacist and prescriber,

23 (6) consistent prescribing of habit-forming drugs.

24 (u-0.5) "Hallucinogen" means a drug that causes markedly
25 altered sensory perception leading to hallucinations of any
26 type.

1 (u-1) "Home infusion services" means services provided by
2 a pharmacy in compounding solutions for direct administration
3 to a patient in a private residence, long-term care facility,
4 or hospice setting by means of parenteral, intravenous,
5 intramuscular, subcutaneous, or intraspinal infusion.

6 (u-5) "Illinois State Police" means the Illinois State
7 Police or its successor agency.

8 (v) "Immediate precursor" means a substance:

9 (1) which the Department has found to be and by rule
10 designated as being a principal compound used, or produced
11 primarily for use, in the manufacture of a controlled
12 substance;

13 (2) which is an immediate chemical intermediary used
14 or likely to be used in the manufacture of such controlled
15 substance; and

16 (3) the control of which is necessary to prevent,
17 curtail or limit the manufacture of such controlled
18 substance.

19 (w) "Instructional activities" means the acts of teaching,
20 educating or instructing by practitioners using controlled
21 substances within educational facilities approved by the State
22 Board of Education or its successor agency.

23 (x) "Local authorities" means a duly organized State,
24 County or Municipal peace unit or police force.

25 (y) "Look-alike substance" means a substance, other than a
26 controlled substance which (1) by overall dosage unit

1 appearance, including shape, color, size, markings or lack
2 thereof, taste, consistency, or any other identifying physical
3 characteristic of the substance, would lead a reasonable
4 person to believe that the substance is a controlled
5 substance, or (2) is expressly or impliedly represented to be
6 a controlled substance or is distributed under circumstances
7 which would lead a reasonable person to believe that the
8 substance is a controlled substance. For the purpose of
9 determining whether the representations made or the
10 circumstances of the distribution would lead a reasonable
11 person to believe the substance to be a controlled substance
12 under this clause (2) of subsection (y), the court or other
13 authority may consider the following factors in addition to
14 any other factor that may be relevant:

15 (a) statements made by the owner or person in control
16 of the substance concerning its nature, use or effect;

17 (b) statements made to the buyer or recipient that the
18 substance may be resold for profit;

19 (c) whether the substance is packaged in a manner
20 normally used for the illegal distribution of controlled
21 substances;

22 (d) whether the distribution or attempted distribution
23 included an exchange of or demand for money or other
24 property as consideration, and whether the amount of the
25 consideration was substantially greater than the
26 reasonable retail market value of the substance.

1 Clause (1) of this subsection (y) shall not apply to a
2 noncontrolled substance in its finished dosage form that was
3 initially introduced into commerce prior to the initial
4 introduction into commerce of a controlled substance in its
5 finished dosage form which it may substantially resemble.

6 Nothing in this subsection (y) prohibits the dispensing or
7 distributing of noncontrolled substances by persons authorized
8 to dispense and distribute controlled substances under this
9 Act, provided that such action would be deemed to be carried
10 out in good faith under subsection (u) if the substances
11 involved were controlled substances.

12 Nothing in this subsection (y) or in this Act prohibits
13 the manufacture, preparation, propagation, compounding,
14 processing, packaging, advertising or distribution of a drug
15 or drugs by any person registered pursuant to Section 510 of
16 the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).

17 (y-1) "Mail-order pharmacy" means a pharmacy that is
18 located in a state of the United States that delivers,
19 dispenses or distributes, through the United States Postal
20 Service or other common carrier, to Illinois residents, any
21 substance which requires a prescription.

22 (z) "Manufacture" means the production, preparation,
23 propagation, compounding, conversion or processing of a
24 controlled substance other than methamphetamine, either
25 directly or indirectly, by extraction from substances of
26 natural origin, or independently by means of chemical

1 synthesis, or by a combination of extraction and chemical
2 synthesis, and includes any packaging or repackaging of the
3 substance or labeling of its container, except that this term
4 does not include:

5 (1) by an ultimate user, the preparation or
6 compounding of a controlled substance for his or her own
7 use;

8 (2) by a practitioner, or his or her authorized agent
9 under his or her supervision, the preparation,
10 compounding, packaging, or labeling of a controlled
11 substance:

12 (a) as an incident to his or her administering or
13 dispensing of a controlled substance in the course of
14 his or her professional practice; or

15 (b) as an incident to lawful research, teaching or
16 chemical analysis and not for sale; or

17 (3) the packaging, repackaging, or labeling of drugs
18 only to the extent permitted under the Illinois Drug Reuse
19 Opportunity Program Act.

20 (z-1) (Blank).

21 (z-5) "Medication shopping" means the conduct prohibited
22 under subsection (a) of Section 314.5 of this Act.

23 (z-10) "Mid-level practitioner" means (i) a physician
24 assistant ~~who has been delegated authority to prescribe~~
25 ~~through a written delegation of authority by a physician~~
26 ~~licensed to practice medicine in all of its branches, in~~

1 ~~accordance with Section 7.5 of the Physician Assistant~~
2 ~~Practice Act of 1987,~~ (ii) an advanced practice registered
3 nurse who has been delegated authority to prescribe through a
4 written delegation of authority by a physician licensed to
5 practice medicine in all of its branches or by a podiatric
6 physician, in accordance with Section 65-40 of the Nurse
7 Practice Act, (iii) an advanced practice registered nurse
8 certified as a nurse practitioner, nurse midwife, or clinical
9 nurse specialist who has been granted authority to prescribe
10 by a hospital affiliate in accordance with Section 65-45 of
11 the Nurse Practice Act, (iv) an animal euthanasia agency, or
12 (v) a prescribing psychologist.

13 (aa) "Narcotic drug" means any of the following, whether
14 produced directly or indirectly by extraction from substances
15 of vegetable origin, or independently by means of chemical
16 synthesis, or by a combination of extraction and chemical
17 synthesis:

18 (1) opium, opiates, derivatives of opium and opiates,
19 including their isomers, esters, ethers, salts, and salts
20 of isomers, esters, and ethers, whenever the existence of
21 such isomers, esters, ethers, and salts is possible within
22 the specific chemical designation; however the term
23 "narcotic drug" does not include the isoquinoline
24 alkaloids of opium;

25 (2) (blank);

26 (3) opium poppy and poppy straw;

1 (4) coca leaves, except coca leaves and extracts of
2 coca leaves from which substantially all of the cocaine
3 and ecgonine, and their isomers, derivatives and salts,
4 have been removed;

5 (5) cocaine, its salts, optical and geometric isomers,
6 and salts of isomers;

7 (6) ecgonine, its derivatives, their salts, isomers,
8 and salts of isomers;

9 (7) any compound, mixture, or preparation which
10 contains any quantity of any of the substances referred to
11 in subparagraphs (1) through (6).

12 (bb) "Nurse" means a registered nurse licensed under the
13 Nurse Practice Act.

14 (cc) (Blank).

15 (dd) "Opiate" means a drug derived from or related to
16 opium.

17 (ee) "Opium poppy" means the plant of the species *Papaver*
18 *somniferum* L., except its seeds.

19 (ee-5) "Oral dosage" means a tablet, capsule, elixir, or
20 solution or other liquid form of medication intended for
21 administration by mouth, but the term does not include a form
22 of medication intended for buccal, sublingual, or transmucosal
23 administration.

24 (ff) "Parole and Pardon Board" means the Parole and Pardon
25 Board of the State of Illinois or its successor agency.

26 (gg) "Person" means any individual, corporation,

1 mail-order pharmacy, government or governmental subdivision or
2 agency, business trust, estate, trust, partnership or
3 association, or any other entity.

4 (hh) "Pharmacist" means any person who holds a license or
5 certificate of registration as a registered pharmacist, a
6 local registered pharmacist or a registered assistant
7 pharmacist under the Pharmacy Practice Act.

8 (ii) "Pharmacy" means any store, ship or other place in
9 which pharmacy is authorized to be practiced under the
10 Pharmacy Practice Act.

11 (ii-5) "Pharmacy shopping" means the conduct prohibited
12 under subsection (b) of Section 314.5 of this Act.

13 (ii-10) "Physician" (except when the context otherwise
14 requires) means a person licensed to practice medicine in all
15 of its branches.

16 (jj) "Poppy straw" means all parts, except the seeds, of
17 the opium poppy, after mowing.

18 (kk) "Practitioner" means a physician licensed to practice
19 medicine in all its branches, dentist, optometrist, podiatric
20 physician, veterinarian, scientific investigator, pharmacist,
21 physician assistant, advanced practice registered nurse,
22 licensed practical nurse, registered nurse, emergency medical
23 services personnel, hospital, laboratory, or pharmacy, or
24 other person licensed, registered, or otherwise lawfully
25 permitted by the United States or this State to distribute,
26 dispense, conduct research with respect to, administer or use

1 in teaching or chemical analysis, a controlled substance in
2 the course of professional practice or research.

3 (ll) "Pre-printed prescription" means a written
4 prescription upon which the designated drug has been indicated
5 prior to the time of issuance; the term does not mean a written
6 prescription that is individually generated by machine or
7 computer in the prescriber's office.

8 (mm) "Prescriber" means a physician licensed to practice
9 medicine in all its branches, dentist, optometrist,
10 prescribing psychologist licensed under Section 4.2 of the
11 Clinical Psychologist Licensing Act with prescriptive
12 authority delegated under Section 4.3 of the Clinical
13 Psychologist Licensing Act, podiatric physician, or
14 veterinarian who issues a prescription, a physician assistant
15 who issues a prescription for a controlled substance in
16 accordance with Section 303.05, ~~a written delegation, and a~~
17 ~~written collaborative agreement required under Section 7.5 of~~
18 ~~the Physician Assistant Practice Act of 1987,~~ an advanced
19 practice registered nurse with prescriptive authority
20 delegated under Section 65-40 of the Nurse Practice Act and in
21 accordance with Section 303.05, a written delegation, and a
22 written collaborative agreement under Section 65-35 of the
23 Nurse Practice Act, an advanced practice registered nurse
24 certified as a nurse practitioner, nurse midwife, or clinical
25 nurse specialist who has been granted authority to prescribe
26 by a hospital affiliate in accordance with Section 65-45 of

1 the Nurse Practice Act and in accordance with Section 303.05,
2 or an advanced practice registered nurse certified as a nurse
3 practitioner, nurse midwife, or clinical nurse specialist who
4 has full practice authority pursuant to Section 65-43 of the
5 Nurse Practice Act.

6 (nn) "Prescription" means a written, facsimile, or oral
7 order, or an electronic order that complies with applicable
8 federal requirements, of a physician licensed to practice
9 medicine in all its branches, dentist, podiatric physician or
10 veterinarian for any controlled substance, of an optometrist
11 in accordance with Section 15.1 of the Illinois Optometric
12 Practice Act of 1987, of a prescribing psychologist licensed
13 under Section 4.2 of the Clinical Psychologist Licensing Act
14 with prescriptive authority delegated under Section 4.3 of the
15 Clinical Psychologist Licensing Act, of a physician assistant
16 for a controlled substance in accordance with Section 303.05,
17 a written delegation, and a written collaborative agreement
18 required under Section 7.5 of the Physician Assistant Practice
19 Act of 1987, of an advanced practice registered nurse with
20 prescriptive authority delegated under Section 65-40 of the
21 Nurse Practice Act who issues a prescription for a controlled
22 substance in accordance with Section 303.05, a written
23 delegation, and a written collaborative agreement under
24 Section 65-35 of the Nurse Practice Act, of an advanced
25 practice registered nurse certified as a nurse practitioner,
26 nurse midwife, or clinical nurse specialist who has been

1 granted authority to prescribe by a hospital affiliate in
2 accordance with Section 65-45 of the Nurse Practice Act and in
3 accordance with Section 303.05 when required by law, or of an
4 advanced practice registered nurse certified as a nurse
5 practitioner, nurse midwife, or clinical nurse specialist who
6 has full practice authority pursuant to Section 65-43 of the
7 Nurse Practice Act.

8 (nn-5) "Prescription Information Library" (PIL) means an
9 electronic library that contains reported controlled substance
10 data.

11 (nn-10) "Prescription Monitoring Program" (PMP) means the
12 entity that collects, tracks, and stores reported data on
13 controlled substances and select drugs pursuant to Section
14 316.

15 (oo) "Production" or "produce" means manufacture,
16 planting, cultivating, growing, or harvesting of a controlled
17 substance other than methamphetamine.

18 (pp) "Registrant" means every person who is required to
19 register under Section 302 of this Act.

20 (qq) "Registry number" means the number assigned to each
21 person authorized to handle controlled substances under the
22 laws of the United States and of this State.

23 (qq-5) "Secretary" means, as the context requires, either
24 the Secretary of the Department or the Secretary of the
25 Department of Financial and Professional Regulation, and the
26 Secretary's designated agents.

1 (rr) "State" includes the State of Illinois and any state,
2 district, commonwealth, territory, insular possession thereof,
3 and any area subject to the legal authority of the United
4 States of America.

5 (rr-5) "Stimulant" means any drug that (i) causes an
6 overall excitation of central nervous system functions, (ii)
7 causes impaired consciousness and awareness, and (iii) can be
8 habit-forming or lead to a substance use disorder, including,
9 but not limited to, amphetamines and their analogs,
10 methylphenidate and its analogs, cocaine, and phencyclidine
11 and its analogs.

12 (rr-10) "Synthetic drug" includes, but is not limited to,
13 any synthetic cannabinoids or piperazines or any synthetic
14 cathinones as provided for in Schedule I.

15 (ss) "Ultimate user" means a person who lawfully possesses
16 a controlled substance for his or her own use or for the use of
17 a member of his or her household or for administering to an
18 animal owned by him or her or by a member of his or her
19 household.

20 (Source: P.A. 102-389, eff. 1-1-22; 102-538, eff. 8-20-21;
21 102-813, eff. 5-13-22; 103-881, eff. 1-1-25.)

22 (720 ILCS 570/303.05)

23 Sec. 303.05. Mid-level practitioner registration.

24 (a) The Department of Financial and Professional
25 Regulation shall register licensed physician assistants,

1 licensed advanced practice registered nurses, and prescribing
2 psychologists licensed under Section 4.2 of the Clinical
3 Psychologist Licensing Act to prescribe and dispense
4 controlled substances under Section 303 and euthanasia
5 agencies to purchase, store, or administer animal euthanasia
6 drugs under the following circumstances:

7 (1) with respect to physician assistants,

8 ~~(A) the physician assistant has been delegated~~
9 ~~written authority to prescribe any Schedule III~~
10 ~~through V controlled substances by a physician~~
11 ~~licensed to practice medicine in all its branches in~~
12 ~~accordance with Section 7.5 of the Physician Assistant~~
13 ~~Practice Act of 1987; and the physician assistant has~~
14 ~~completed the appropriate application forms and has~~
15 ~~paid the required fees as set by rule; or~~

16 ~~(B) the physician assistant has been delegated~~
17 ~~authority by a collaborating physician licensed to~~
18 ~~practice medicine in all its branches to prescribe or~~
19 ~~dispense Schedule II controlled substances through a~~
20 ~~written delegation of authority and under the~~
21 ~~following conditions:~~

22 ~~(i) Specific Schedule II controlled substances~~
23 ~~by oral dosage or topical or transdermal~~
24 ~~application may be delegated, provided that the~~
25 ~~delegated Schedule II controlled substances are~~
26 ~~routinely prescribed by the collaborating~~

1 ~~physician. This delegation must identify the~~
2 ~~specific Schedule II controlled substances by~~
3 ~~either brand name or generic name. Schedule II~~
4 ~~controlled substances to be delivered by injection~~
5 ~~or other route of administration may not be~~
6 ~~delegated;~~

7 ~~(ii) any delegation must be of controlled~~
8 ~~substances prescribed by the collaborating~~
9 ~~physician;~~

10 ~~(iii) all prescriptions must be limited to no~~
11 ~~more than a 30-day supply, with any continuation~~
12 ~~authorized only after prior approval of the~~
13 ~~collaborating physician;~~

14 ~~(iv) the physician assistant must discuss the~~
15 ~~condition of any patients for whom a controlled~~
16 ~~substance is prescribed monthly with the~~
17 ~~delegating physician;~~

18 (A) ~~(v)~~ the physician assistant must have
19 completed the appropriate application forms and paid
20 the required fees as set by rule;

21 (B) ~~(vi)~~ the physician assistant must provide
22 evidence of satisfactory completion of 45 contact
23 hours in pharmacology from any physician assistant
24 program accredited by the Accreditation Review
25 Commission on Education for the Physician Assistant
26 (ARC-PA), or its predecessor agency, for any new

1 license issued with Schedule II authority after the
2 effective date of this amendatory Act of the 97th
3 General Assembly; and

4 (C) ~~(vii)~~ the physician assistant must annually
5 complete at least 5 hours of continuing education in
6 pharmacology;

7 (2) with respect to advanced practice registered
8 nurses who do not meet the requirements of Section 65-43
9 of the Nurse Practice Act,

10 (A) the advanced practice registered nurse has
11 been delegated authority to prescribe any Schedule III
12 through V controlled substances by a collaborating
13 physician licensed to practice medicine in all its
14 branches or a collaborating podiatric physician in
15 accordance with Section 65-40 of the Nurse Practice
16 Act. The advanced practice registered nurse has
17 completed the appropriate application forms and has
18 paid the required fees as set by rule; or

19 (B) the advanced practice registered nurse has
20 been delegated authority by a collaborating physician
21 licensed to practice medicine in all its branches to
22 prescribe or dispense Schedule II controlled
23 substances through a written delegation of authority
24 and under the following conditions:

25 (i) specific Schedule II controlled substances
26 by oral dosage or topical or transdermal

1 application may be delegated, provided that the
2 delegated Schedule II controlled substances are
3 routinely prescribed by the collaborating
4 physician. This delegation must identify the
5 specific Schedule II controlled substances by
6 either brand name or generic name. Schedule II
7 controlled substances to be delivered by injection
8 or other route of administration may not be
9 delegated;

10 (ii) any delegation must be of controlled
11 substances prescribed by the collaborating
12 physician;

13 (iii) all prescriptions must be limited to no
14 more than a 30-day supply, with any continuation
15 authorized only after prior approval of the
16 collaborating physician;

17 (iv) the advanced practice registered nurse
18 must discuss the condition of any patients for
19 whom a controlled substance is prescribed monthly
20 with the delegating physician or in the course of
21 review as required by Section 65-40 of the Nurse
22 Practice Act;

23 (v) the advanced practice registered nurse
24 must have completed the appropriate application
25 forms and paid the required fees as set by rule;

26 (vi) the advanced practice registered nurse

1 must provide evidence of satisfactory completion
2 of at least 45 graduate contact hours in
3 pharmacology for any new license issued with
4 Schedule II authority after the effective date of
5 this amendatory Act of the 97th General Assembly;
6 and

7 (vii) the advanced practice registered nurse
8 must annually complete 5 hours of continuing
9 education in pharmacology;

10 (2.5) with respect to advanced practice registered
11 nurses certified as nurse practitioners, nurse midwives,
12 or clinical nurse specialists who do not meet the
13 requirements of Section 65-43 of the Nurse Practice Act
14 practicing in a hospital affiliate,

15 (A) the advanced practice registered nurse
16 certified as a nurse practitioner, nurse midwife, or
17 clinical nurse specialist has been privileged to
18 prescribe any Schedule II through V controlled
19 substances by the hospital affiliate upon the
20 recommendation of the appropriate physician committee
21 of the hospital affiliate in accordance with Section
22 65-45 of the Nurse Practice Act, has completed the
23 appropriate application forms, and has paid the
24 required fees as set by rule; and

25 (B) an advanced practice registered nurse
26 certified as a nurse practitioner, nurse midwife, or

1 clinical nurse specialist has been privileged to
2 prescribe any Schedule II controlled substances by the
3 hospital affiliate upon the recommendation of the
4 appropriate physician committee of the hospital
5 affiliate, then the following conditions must be met:

6 (i) specific Schedule II controlled substances
7 by oral dosage or topical or transdermal
8 application may be designated, provided that the
9 designated Schedule II controlled substances are
10 routinely prescribed by advanced practice
11 registered nurses in their area of certification;
12 the privileging documents must identify the
13 specific Schedule II controlled substances by
14 either brand name or generic name; privileges to
15 prescribe or dispense Schedule II controlled
16 substances to be delivered by injection or other
17 route of administration may not be granted;

18 (ii) any privileges must be controlled
19 substances limited to the practice of the advanced
20 practice registered nurse;

21 (iii) any prescription must be limited to no
22 more than a 30-day supply;

23 (iv) the advanced practice registered nurse
24 must discuss the condition of any patients for
25 whom a controlled substance is prescribed monthly
26 with the appropriate physician committee of the

1 hospital affiliate or its physician designee; and

2 (v) the advanced practice registered nurse
3 must meet the education requirements of this
4 Section;

5 (3) with respect to animal euthanasia agencies, the
6 euthanasia agency has obtained a license from the
7 Department of Financial and Professional Regulation and
8 obtained a registration number from the Department; or

9 (4) with respect to prescribing psychologists, the
10 prescribing psychologist has been delegated authority to
11 prescribe any nonnarcotic Schedule III through V
12 controlled substances by a collaborating physician
13 licensed to practice medicine in all its branches in
14 accordance with Section 4.3 of the Clinical Psychologist
15 Licensing Act, and the prescribing psychologist has
16 completed the appropriate application forms and has paid
17 the required fees as set by rule.

18 (b) The mid-level practitioner shall only be licensed to
19 prescribe those schedules of controlled substances for which a
20 licensed physician has delegated prescriptive authority,
21 except that an animal euthanasia agency does not have any
22 prescriptive authority and a physician assistant shall have
23 prescriptive authority in accordance with the Physician
24 Assistant Practice Act of 1987 without delegation by a
25 physician. ~~An A-physician assistant and an~~ advanced practice
26 registered nurse is ~~are~~ prohibited from prescribing

1 medications and controlled substances not set forth in the
2 required written delegation of authority or as authorized by
3 their practice Act.

4 (c) Upon completion of all registration requirements,
5 physician assistants, advanced practice registered nurses, and
6 animal euthanasia agencies may be issued a mid-level
7 practitioner controlled substances license for Illinois.

8 (d) A collaborating physician may, but is not required to,
9 delegate prescriptive authority to an advanced practice
10 registered nurse as part of a written collaborative agreement,
11 and the delegation of prescriptive authority shall conform to
12 the requirements of Section 65-40 of the Nurse Practice Act.

13 (e) (Blank). ~~A collaborating physician may, but is not~~
14 ~~required to, delegate prescriptive authority to a physician~~
15 ~~assistant as part of a written collaborative agreement, and~~
16 ~~the delegation of prescriptive authority shall conform to the~~
17 ~~requirements of Section 7.5 of the Physician Assistant~~
18 ~~Practice Act of 1987.~~

19 (f) Nothing in this Section shall be construed to prohibit
20 generic substitution.

21 (Source: P.A. 99-173, eff. 7-29-15; 100-453, eff. 8-25-17;
22 100-513, eff. 1-1-18; 100-863, eff. 8-14-18.)

23 Section 99. Effective date. This Act takes effect upon
24 becoming law, except that Section 7.9 of the Physician
25 Assistant Practice Act of 1987 takes effect January 1, 2028."